Date published: 2025-11-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

IRR Inhibitors

IRR inhibitors, also known as ionizing radiation response inhibitors, are a class of chemical compounds designed to modulate cellular responses to ionizing radiation (IR). Ionizing radiation, such as X-rays and gamma rays, induces various DNA lesions and damages, triggering intricate cellular signaling pathways. IRR inhibitors specifically target key components within these signaling cascades, aiming to regulate the cellular response to radiation stress.

These inhibitors play a crucial role in understanding the molecular mechanisms underlying the cellular reactions to ionizing radiation, which is essential for advancing both basic scientific knowledge and potential applications in various fields. One prominent example of IRR inhibitors is those targeting the DNA damage response (DDR) pathway. The DDR pathway is an intricate network of signaling events that coordinates cell cycle checkpoints, DNA repair, and apoptosis in response to DNA damage induced by ionizing radiation. IRR inhibitors may interact with proteins involved in DDR, such as ATM (ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia and Rad3-related), to modulate their activities. By influencing these critical components, IRR inhibitors provide researchers with valuable tools to dissect the molecular intricacies of cellular responses to ionizing radiation. Understanding the underlying biology facilitated by IRR inhibitors contributes to a broader comprehension of DNA repair mechanisms and aids in the identification of potential targets for further investigation and research in the field of radiation biology.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$85.00
$132.00
$287.00
$495.00
$3752.00
42
(0)

Erlotinib is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR), and could indirectly affect INSRR.

Lapatinib

231277-92-2sc-353658
100 mg
$412.00
32
(1)

Lapatinib is an antineoplastic agent used in breast cancer research

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs). This could indirectly influence the function of the INSRR.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Sorafenib is a kinase inhibitor that decreases tumor cell proliferation. It could indirectly impact the INSRR protein through its activity on various kinases.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Dasatinib is a multi-targeted kinase inhibitor, known to inhibit more than 19 different kinases and could indirectly impact the function of the INSRR.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. It could have an indirect effect on INSRR activity.

AP 24534

943319-70-8sc-362710
sc-362710A
10 mg
50 mg
$172.00
$964.00
2
(1)

AP 24534 is a multi-targeted kinase inhibitor. Its targets include BCR-ABL, an abnormal tyrosine kinase that is expressed in most cases of chronic myelogenous leukemia. This could impact the INSRR indirectly.

Afatinib-d4

850140-72-6 (unlabeled)sc-481821
10 mg
$4665.00
(0)

BIBW2992 is an available, irreversible inhibitor of EGFR and HER2. It could indirectly impact INSRR.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$205.00
$405.00
9
(1)

Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor that is studied in the research of chronic myeloid leukemia (CML). It could indirectly affect INSRR.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Gefitinib is an EGFR inhibitor, like erlotinib, which could indirectly affect the INSRR protein.